After being informed about the study and potential risks, all patients giving written informed consent will undergo a 4 weeks screening period to determine eligibility for study entry. At Week 0, patients who meet eligibility requirements will be given L-glutamine (15 grams, twice daily)
The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment for patients with diverticulosis.